Oncology

Researchers assessed balugrastim’s efficacy, safety, and tolerability in 4 different clinical trials and found it to be a suitable alternative to pegfilgrastim in regard to reducing the mean duration of severe neutropenia.

Promotional advertising by cancer centers has seen a dramatic spike in recent years, with 890 cancer centers spending $173 million for advertising in 2014.

The National Cancer Institute (NCI) estimates that the aging US population will contribute to a substantial increase in the number of older cancer survivors over the next 25 years.

According to a study conducted in the United Kingdom, statins can reduce the risk of dying from breast, prostate, lung, and bowel cancer.

This week in managed care, the top stories included a report on how much Americans spend on complementary health approaches, more trouble with the Affordable Care Act's risk adjustment program, and researchers linked the BRCA1 gene to deadly uterine cancer.

A nomogram could help to predict patients at risk of Grade 4 neutropenia during treatment, according to a study published in Clinical Genitourinary Cancer.

Experts at a summit convened by the National Comprehensive Cancer Network (NCCN) agreed that progress in health information technology can help break the walls between compartmentalized data that lives within distinct data systems, to improve patient outcomes.

The rising prevalence of urologic cancers, along with the increased use of hormone therapies and the approval of novel biologics, is driving strong growth in the urologic cancer market globally through 2022.

The FDA has asked Juno Therapeutics to halt the phase 2 clinical trial of JCAR015 in adult patients with relapsed or refractory B cell acute lymphoblastic leukemia, the ROCKET trial.

Panelists at the policy summit hosted by National Comprehensive Cancer Network agreed that sharing information can help create a learning system that can improve patient outcomes.

Michael Kolodziej, MD, national medical director for oncology strategy at Aetna, said that the evaluation of academic medical centers has allowed the company to examine what lies at the heart of creating optimal patient outcomes and experiences.

The American Society of Clinical Oncology (ASCO) has published a paper that shares the various innovative approaches developed by the society for guideline development and implementation.

A federal appeals court has overturned a previous ruling and decided that biosimilar manufacturers must provide the innovator company a 180-day notice only after receiving FDA-approval for its biosimilar product.

The approval was based on the results of the phase 3 ENDEAVOR study.

Researchers from the Duke Cancer Institute have discovered that mutations in the BRCA1 gene can dramatically increase the probability of a woman developing serous or serous-like endometrial carcinoma.

Gregory C. Simon, executive director, White House Cancer Task Force, spoke at the National Comprehensive Cancer Network Policy Summit, held just 2 days before the Cancer Moonshot Summit.